BELLEVILLE, ON, Aug. 25 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
announced today that its U.S. Animal Health business, Bioniche Animal Health
USA, Inc., has been granted full listing by the Organic Materials Review
Institute (OMRI) for its premier immunostimulant technology for calves,
Immunoboost. The addition of Immunoboost to the official OMRI list indicates
that this biological product has met the national standard for use in organic
dairy and beef operations in the United States.
Immunoboost is USDA-licensed for use in calves between the ages of one
and five days, as a one-time immunotherapeutic treatment for reduction of the
mortality and morbidities associated with calf scours caused by E. coli (K99)
Immunoboost is a mycobacterial cell wall extract (MCWE) formulation. A
distinct and more advanced Bioniche technology that also uses mycobacterial
cell walls - Mycobacterial Cell Wall-DNA Complex (MCC) - is currently
undergoing Phase III clinical testing in human patients with
non-muscle-invasive bladder cancer in 31 North American urology centres.
Recognized experts in organic dairy and beef operations are pleased to
have recourse to Immunoboost for the treatment of calf scours. Dr. Hubert
Karreman, a Pennsylvania dairy veterinarian, has consulted on organic health
care issues with veterinarians across the U.S. for over a decade and recently
authored a book entitled, "Treating Dairy Cows Naturally: Thoughts and
"Enhancing the immune system is essential in helping animals to heal,"
said Dr. Karreman. "With immunologic stimulation so critical to maintaining or
enhancing health, I believe it is a wise choice to use Immunoboost as a
therapeutic agent for all kinds of livestock production systems. Immunoboost
is an effective, non-antibiotic treatment that has come of age and, being OMRI
listed, it now provides the necessary assurance to organic producers and the
veterinarians that service these specialized farms."
Dr. Karreman works with over 85 certified and transitioning organic
herds, and is a sought-after speaker on organic practices at both veterinary
and producer conferences.
"Immunoboost has recently gained market interest in the organic sector,"
said Mr. Jim Phillips, President, Bioniche Animal Health (global). "Its
listing by OMRI comes at a time when antibiotic use is being carefully
scrutinized by the industry and its customers, with alternatives to
antibiotics being sought."
Agriculture and Agri-Food Canada stated in a report that the natural beef
market in the U.S. is one of the fastest growing segments of the beef market,
driven by healthier eating choices, food scares and health-related issues. The
U.S. natural beef sector is estimated to be worth US$500 to US$550 million
annually, or 1% of the total U.S. beef market. Overall beef sales in the U.S.
have been slowing since peaking in the 1970's, and overall beef production
figures continue to decline. However, the natural beef sector is growing by
roughly 20% annually.
The Organic Materials Review Institute (OMRI) is a national non-profit
organization that determines which input products are allowed for use in
organic production and processing. Only OMRI Listed products may be used on
operations that are certified organic under the USDA National Organic Program.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of Canada's Top Ten Life Sciences
Companies for 2008. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Jennifer Shea, Vice-President, Communications,
Investor & Government Relations, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com